Effects of S-1 and Capecitabine on Coronary Artery Blood Flow
Status:
Terminated
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are
occasionally associated with cardiac toxicity. Clinical fluoropyrimidine cardiotoxicity is
infrequent, but subclinical toxicity may be much more common. Cardiac toxicity may be less
frequent with S-1 as compared with 5-fluorouracil and capecitabine, but head-to-head
comparisons are lacking. The purpose of the study is to compare 2 measures of subclinical
coronary artery microvascular dysfunction, the coronary flow reserve and the coronary flow
response to a cold pressor test, in a patient population who are being treated for
adenocarcinoma of the gastrointestinal tract with one of 2 oxaliplatin-containing regimens,
either with oxaliplatin plus S-1 or with oxaliplatin plus capecitabine.